Trxade Group Inc. (NASDAQ:MEDS) went up by 71.76% from its latest closing price compared to the recent 1-year high of $8.00. The company’s stock price has collected 8.22% of gains in the last five trading sessions. Press Release reported 1 hour ago that TRxADE HEALTH, INC. Announces Launch of MedCheks Health Passport App for iOS Devices
Is It Worth Investing in Trxade Group Inc. (NASDAQ :MEDS) Right Now?
Plus, the 36-month beta value for MEDS is at 1.17. Opinions of the stock are interesting as 3 analysts out of 3 who provided ratings for Trxade Group Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $9.25. MEDS currently public float of 3.28M and currently shorts hold a 0.10% ratio of that float. Today, the average trading volume of MEDS was 75.68K shares.
MEDS’s Market Performance
MEDS stocks went up by 8.22% for the week, with a monthly jump of 14.61% and a quarterly performance of -34.19%, while its annual performance rate touched -33.33%. The volatility ratio for the week stands at 5.95% while the volatility levels for the past 30 days are set at 5.85% for Trxade Group Inc.. The simple moving average for the period of the last 20 days is 97.07% for MEDS stocks with a simple moving average of 30.22% for the last 200 days.
MEDS Trading at 69.19% from the 50-Day Moving Average
After a stumble in the market that brought MEDS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.40% of loss for the given period.
Volatility was left at 5.85%, however, over the last 30 days, the volatility rate increased by 5.95%, as shares surge +103.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +23.22% upper at present.
During the last 5 trading sessions, MEDS rose by +68.06%, which changed the moving average for the period of 200-days by +14.23% in comparison to the 20-day moving average, which settled at $3.72. In addition, Trxade Group Inc. saw -22.87% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at MEDS starting from Patel Prashant, who sale 7,500 shares at the price of $4.39 back on Apr 19. After this action, Patel Prashant now owns 1,252,500 shares of Trxade Group Inc., valued at $32,909 using the latest closing price.
PETERSON MICHAEL L, the Director of Trxade Group Inc., sale 900 shares at $4.68 during a trade that took place back on Apr 19, which means that PETERSON MICHAEL L is holding 6,287 shares at $4,212 based on the most recent closing price.
Stock Fundamentals for MEDS
Current profitability levels for the company are sitting at:
- -10.40 for the present operating margin
- +33.33 for the gross margin
The net margin for Trxade Group Inc. stands at -14.81. The total capital return value is set at -24.66, while invested capital returns managed to touch -36.23. Equity return is now at value -35.60, with -31.30 for asset returns.
Based on Trxade Group Inc. (MEDS), the company’s capital structure generated 7.23 points at debt to equity in total, while total debt to capital is 6.74. Total debt to assets is 6.41, with long-term debt to equity ratio resting at 3.13. Finally, the long-term debt to capital ratio is 2.92.
When we switch over and look at the enterprise to sales, we see a ratio of 2.07, with the company’s debt to enterprise value settled at 0.02. The receivables turnover for the company is 12.76 and the total asset turnover is 2.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.95.